Business context and reporting period
The filing is AcelRx Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2018. The request metadata names TALPHERA, INC., but the filing itself identifies the registrant as AcelRx Pharmaceuticals, Inc.
AcelRx was developing and preparing to commercialize acute-pain therapies DSUVIA/DZUVEO and Zalviso. After quarter-end, on November 2, 2018, the FDA approved DSUVIA for use in adults in certified medically supervised healthcare settings. The company anticipated a U.S. launch in Q1 2019.
Financial results and liquidity
Amounts below are in millions of dollars except per-share data.
| Metric | Q3 2018 | Q3 2017 | Nine months 2018 | Nine months 2017 |
|---|---|---|---|---|
| Revenue | $0.377 | $1.487 | $1.538 | $7.255 |
| Operating expenses | $9.705 | $10.348 | $26.288 | $38.130 |
| Operating loss | $(9.328) | $(8.861) | $(24.750) | $(30.875) |
| Net loss | $(12.458) | $(13.013) | $(34.591) | $(41.623) |
| Basic and diluted loss per share | $(0.21) | $(0.28) | $(0.64) | $(0.91) |
- Revenue and costs: Collaboration revenue fell substantially, primarily because Grunenthal was drawing down existing Zalviso inventory. Research and development expense declined 34% year over year for the nine-month period, mainly following completion of Zalviso Phase 3 development. General and administrative expense rose 3% for the same period as the company prepared for DSUVIA commercialization.
- Cash flow: Operating activities used $20.1 million in the first nine months, compared with $23.1 million in 2017. Investing activities provided $1.1 million; financing activities provided $23.7 million, including $29.1 million of net equity proceeds, partly offset by $5.7 million of debt payments.
- Liquidity: At September 30, cash and cash equivalents were $57.6 million and short-term investments were $6.0 million, totaling $63.6 million. Management expected resources to fund operations through at least Q4 2019, while warning they likely would not fund operations until sustainable revenue is achieved.
- Debt and other liabilities: Hercules debt was $13.9 million, with scheduled maturity in March 2020 and a security interest in substantially all assets other than intellectual property. The liability associated with monetized future royalties was $92.1 million, including $8.7 million of non-cash interest expense for the nine months.
- Margins and profitability: Total cost of goods sold exceeded total revenue by approximately $0.5 million in Q3 and $1.2 million for the nine months. The company anticipated negative gross margins on Zalviso product supplied to Grunenthal for the foreseeable future.
Material changes, outlook, and risks
- Nine-month net loss improved by $7.0 million year over year, while Q3 operating loss increased by $0.5 million. The company attributed the lower year-to-date loss principally to reduced operating expenses.
- In July and August 2018, AcelRx completed a public offering of 8.36 million shares, generating $21.7 million net proceeds; it also raised $7.4 million net through its ATM program during the nine-month period. Shares outstanding increased from 50.9 million at year-end 2017 to 61.8 million at September 30, 2018.
- Management planned to launch DSUVIA in the United States in Q1 2019 and was evaluating when to resubmit the Zalviso NDA. DZUVEO had European approval, but the company had not secured a European commercialization partner.
- Key risks include DSUVIA market uptake, pricing and reimbursement, formulary access, opioid-related regulation and REMS obligations, manufacturing and supply concentration, Zalviso regulatory uncertainty, dependence on Grunenthal, and the need for additional capital. The filing states that future financing may be unavailable or dilutive.
- The DoD contract, which reimbursed eligible DSUVIA development costs, was extended through February 28, 2019. DoD costs remain subject to audit. The company reported no material legal proceedings and no material changes in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is for AcelRx Pharmaceuticals, Inc., although the request metadata says TALPHERA, INC.
- Review DSUVIA’s approved label, required REMS, commercial launch progress, manufacturing readiness, and actual adoption, pricing, and reimbursement.
- Check the timing and FDA outcome of any Zalviso NDA resubmission, including whether device-error or inadvertent-dispensing issues require further work.
- Assess cash burn against the stated Q4 2019 liquidity horizon, potential financing needs, and the effects of further equity issuance.
- Track Grunenthal’s Zalviso sales and inventory levels, the royalty share retained after monetization, and the substantial royalty-related liability.